Cayman Balaglitazone

Balaglitazone is a partial agonist of peroxisome proliferator-activated receptor γ (PPARγ; EC₅₀ = 1.351 μM in a transactivation assay). It decreases non-fasting plasma glucose levels in diabetic db/db mice (ED₉₀ = 3 mg/kg per day). Balaglitazone (5 and 10 mg/kg per day) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in diet-induced obese rats. In doxorubicin-resistant K562 human myelogenous leukemia cells, balaglitazone (25 μM) decreases P-glycoprotein (P-gp) levels, increases intracellular accumulation of the P-gp substrate rhodamine 123 (Item No. ), and sensitizes cells to doxorubicin (Item No. ).

WARNING This product is not for human or veterinary use.